期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 7, 期 6, 页码 863-870出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.7.6.863
关键词
Akt; inhibitors; PI3K; receptor tyrosine kinase; renal cell carcinoma
类别
资金
- NCI NIH HHS [1R21CA 91259-01A1] Funding Source: Medline
Kidney cancer, or renal cell carcinoma, is a relatively rare malignancy but is metastatic at diagnosis in a third of patients; metastatic disease has a dismal prognosis. Conventional chemotherapy has been woefully inadequate, thus novel targets for 'designer' therapies are being actively evaluated. The PI3K-Akt signaling cascade, owing to its dual role in both survival and mitogenic signaling, is in theory an ideal therapeutic target for this disease, but may also represent its fatal flaw. Thus, largely due to toxicity issues, no PI3K or Akt inhibitors are currently ready for clinical application. In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据